Rifaximin Therapy for Patients with Irritable Bowel Syndrome without Constipation
Open accessThe DOI matches its Crossref record; 21 of the 21 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Evidence suggests that gut flora may play an important role in the pathophysiology of the irritable bowel syndrome (IBS). We evaluated rifaximin, a minimally absorbed antibiotic, as treatment for IBS. METHODS: In two identically designed, phase 3, double-blind, placebo-controlled trials (TARGET 1 and TARGET 2), patients who had IBS without constipation were randomly assigned to either rifaximin at a dose of 550 mg or placebo, three times daily for 2 weeks, and were followed for an additional 10 weeks. The primary end point, the proportion of patients who had adequate relief of global IBS symptoms, and the key secondary end point, the proportion of patients who had adequate relief of IBS-related bloating, were assessed weekly. Adequate relief was defined as self-reported relief of symptoms for at least 2 of the first 4 weeks after treatment. Other secondary end points included the percentage of patients who had a response to treatment as assessed by daily self-ratings of global IBS symptoms and individual symptoms of bloating, abdominal pain, and stool consistency during the 4 weeks after treatment and during the entire 3 months of the study. RESULTS: Significantly more patients in the rifaximin group than in the placebo group had adequate relief of global IBS symptoms during the first 4 weeks after treatment (40.8% vs. 31.2%, P=0.01, in TARGET 1; 40.6% vs. 32.2%, P=0.03, in TARGET 2; 40.7% vs. 31.7%, P<0.001, in the two studies combined). Similarly, more patients in the rifaximin group than in the placebo group had adequate relief of bloating (39.5% vs. 28.7%, P=0.005, in TARGET 1; 41.0% vs. 31.9%, P=0.02, in TARGET 2; 40.2% vs. 30.3%, P<0.001, in the two studies combined). In addition, significantly more patients in the rifaximin group had a response to treatment as assessed by daily ratings of IBS symptoms, bloating, abdominal pain, and stool consistency. The incidence of adverse events was similar in the two groups. CONCLUSIONS: Among patients who had IBS without constipation, treatment with rifaximin for 2 weeks provided significant relief of IBS symptoms, bloating, abdominal pain, and loose or watery stools. (Funded by Salix Pharmaceuticals; ClinicalTrials.gov numbers, NCT00731679 and NCT00724126.).
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Placebo-controlled studies of antibiotic (rifaximin) treatment in FGIDs and IBS have demonstrated significant reduction in bloating scores with rifaximin compared to placebo150–152.”
From The gut Microbiome in adult and pediatric functional gastrointestinal disorders (2019) · cites this paper as [151]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“A short course of a non-absorbable antibiotic such as rifaximin has been shown to moderately improve the symptoms of irritable bowel syndrome (IBS), particularly bloating and flatulence.”
From Intestinal microbiota in functional bowel disorders: a Rome foundation report (2013) · cites this paper as [189]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Moreover, it is likely that patients may require repeated courses of therapy, as trial evidence suggests the benefit diminishes by 12 weeks.189”
From Intestinal microbiota in functional bowel disorders: a Rome foundation report (2013) · cites this paper as [189]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The sample size calculation was based on a one-sided α level of 0·0125 to account for two primary end points, an assumed placebo response rate of 40 % and a treatment difference of 10 % in responder rates based on previously published studies( 23 , 28 ). Further, accounting for a potential 10 % dropout rate and three interim analyses, 580 subjects in each group were required, totalling to 1740 sub”
From Effect of the probiotic strain Bifidobacterium animalis subsp. lactis , BB-12 ® , on defecation frequency in healthy subjects with low defecation frequency and abdominal discomfort: a randomised, double-blind, placebo-controlled, parallel-group trial (2015) · cites this paper as [23]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In addition, treatments that change the microbiota, such as antibiotics or fecal microbiota transplant, 19,20 may be bene fi cial in a subset of patients with IBS.”
From Efficacy of Probiotics in Irritable Bowel Syndrome: Systematic Review and Meta-analysis (2023) · cites this paper as [19]
Experimental — accuracy not yet measured
11 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Functional bowel disorders and functional abdominal pain
Thompson, W. G., Longstreth, G. F., Drossman, D. A., Heaton, K. W., Irvine, E. J., & Müller-Lissner, S. A. (1999) · Gut · doi:10.1136/gut.45.2008.ii43 · Cited by 2,440
Drossman, D. A., Li, Z., Andruzzi, E., Temple, R. D., Talley, N. J., Grant Thompson, W., Whitehead, W. E., Janssens, J., Funch-Jensen, P., Corazziari, E., et al. (1993) · Digestive Diseases and Sciences · doi:10.1007/bf01303162 · Cited by 2,198
Kassinen, A., Krogius-Kurikka, L., Mäkivuokko, H., Rinttilä, T., Paulin, L., Corander, J., Malinen, E., Apajalahti, J., & Palva, A. (2007) · Gastroenterology · doi:10.1053/j.gastro.2007.04.005 · Cited by 1,002
An Evidence-Based Position Statement on the Management of Irritable Bowel Syndrome
American College of Gastroenterology IBS Task Force (2009) · The American Journal of Gastroenterology · doi:10.1038/ajg.2008.122 · Cited by 694
Self-citationPimentel, M. (2003) · The American Journal of Gastroenterology · doi:10.1016/s0002-9270(02)05902-6 · Cited by 669
Self-citationSmall intestinal bacterial overgrowth in patients with irritable bowel syndrome
Posserud, I., Stotzer, P.-O., Björnsson, E. S., Abrahamsson, H., & Simrén, M. (2007) · Gut · doi:10.1136/gut.2006.108712 · Cited by 499
Pimentel, M., Park, S., Mirocha, J., Kane, S. V., & Kong, Y. (2006) · Annals of Internal Medicine · doi:10.7326/0003-4819-145-8-200610170-00004 · Cited by 466
Self-citationSharara, A. I., Aoun, E., Abdul-Baki, H., Mounzer, R., Sidani, S., & ElHajj, I. (2006) · The American Journal of Gastroenterology · doi:10.1111/j.1572-0241.2006.00458.x · Cited by 344
Attar, A., Flourié, B., Rambaud, J., Franchisseur, C., Ruszniewski, P., & Bouhnik, Y. (1999) · Gastroenterology · doi:10.1016/s0016-5085(99)70336-7 · Cited by 234
An Evidence-Based Systematic Review on the Management of Irritable Bowel Syndrome
Brandt, L. J., Chey, W. D., Foxx-Orenstein, A. E., Quigley, E. M. M., Schiller, L. R., Schoenfeld, P. S., Spiegel, B. M., Talley, N. J., & Moayyedi, P. (2009) · American Journal of Gastroenterology · doi:10.14309/00000434-200901001-00002 · Cited by 225
Self-citation
Research works printed but not linked: 1
- El-Serag HB. Impact of irritable bowel syndrome: prevalence and effect on health- related quality of life. Rev Gastroenterol Disord 2003;3:Suppl 2:S3-S11.
Cited by
Items 101–200 of 1,000
Villanueva-Millán, M. J., Leite, G., Wang, J., Morales, W., Parodi, G., Pimentel, M. L., Barlow, G. M., Mathur, R., Rezaie, A. R., Sanchez, M., et al. (2022) · The American Journal of Gastroenterology · doi:10.14309/ajg.0000000000001997 · Cited by 173
“An early breath testing study suggested the importance of gut microbes in IBS (25), and 3 pivotal trials (26,27) led to the US Food and Drug Administration approval of an antibiotic treatment for IBS-D.”
Self-citationIrritable bowel syndrome: the clinical approach
Adriani, A., Ribaldone, D. G., Astegiano, M., Durazzo, M., Saracco, G. M., & Pellicano, R. (2018) · Panminerva Medica · doi:10.23736/s0031-0808.18.03541-3 · Cited by 184
Shukla, R., Ghoshal, U., Dhole, T. N., & Ghoshal, U. C. (2015) · Digestive Diseases and Sciences · doi:10.1007/s10620-015-3607-y · Cited by 166
“Moreover, improvement of symptoms in IBS by manipulation of gut microbiota using probiotics, prebiotics, or antibiotics further suggests that dysbiosis may play a potential role in the pathogenesis of IBS [5–7].”
BackgroundSisson, G., Ayis, S., Sherwood, R. A., & Bjarnason, I. (2014) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.12787 · Cited by 147
Immune Activation in Irritable Bowel Syndrome: Can Neuroimmune Interactions Explain Symptoms?
Hughes, P. A., Zola, H., Penttila, I. A., Blackshaw, A. L., Andrews, J. M., & Krumbiegel, D. (2013) · American Journal of Gastroenterology · doi:10.1038/ajg.2013.120 · Cited by 148
Savarino, E., Zingone, F., Barberio, B., Marasco, G., Akyuz, F., Akpinar, H., Barboi, O., Bodini, G., Bor, S., Chiarioni, G., et al. (2022) · United European Gastroenterology Journal · doi:10.1002/ueg2.12259 · Cited by 146
“001).(140) A subsequent trial assessed the efficacy of rifaximin retreatment.”
BackgroundRao, A. S., Camilleri, M., Eckert, D. J., Busciglio, I., Burton, D. D., Ryks, M., Wong, B. S., Lamsam, J., Singh, R., & Zinsmeister, A. R. (2011) · American Journal of Physiology-Gastrointestinal and Liver Physiology · doi:10.1152/ajpgi.00168.2011 · Cited by 145
Antibiotic Treatment of Constipation-Predominant Irritable Bowel Syndrome
Pimentel, M., Chang, C., Chua, K. S., Mirocha, J., DiBaise, J., Rao, S., & Amichai, M. (2014) · Digestive Diseases and Sciences · doi:10.1007/s10620-014-3157-8 · Cited by 143
Self-citationThe Gut Microbiota and Irritable Bowel Syndrome: Friend or Foe?
Ghoshal, U. C., Shukla, R., Ghoshal, U., Gwee, K.-A., Ng, S. C., & Quigley, E. M. M. (2012) · International Journal of Inflammation · doi:10.1155/2012/151085 · Cited by 144
“3%) [89, 103, 105].”
The effects of gut microbiota on CNS function in humans
Tillisch, K. (2014) · Gut Microbes · doi:10.4161/gmic.29232 · Cited by 144
Randomised clinical trial: rifaximin versus placebo for the treatment of functional dyspepsia
Tan, V. P. Y., Liu, K. S. H., Lam, F. Y. F., Hung, I. F. N., Yuen, M. F., & Leung, W. K. (2017) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.13945 · Cited by 143
“To illustrate the potential role of gut microbiota on the pathogenesis of IBS, Pimentel and colleagues demonstrated significant improvement in abdominal pain and bloating in patients with nonconstipated IBS who were treated with rifaximin, a nonabsorbable systemic antibiotic.(8) Furthermore, Sharara and colleagues dem…”
BackgroundIrritable Bowel Syndrome and the Gut Microbiome: A Comprehensive Review
Shaikh, S. D., Sun, N. Z., Canakis, A., Park, W. Y., & Weber, H. C. (2023) · Journal of Clinical Medicine · doi:10.3390/jcm12072558 · Cited by 190
“It has been postulated that antibiotics alter the gut microbial composition, reducing harmful bacterial products and altering inflammatory and immune responses [141].”
BackgroundMethodInfluentialRingel-Kulka, T., Choi, C. H., Temas, D., Kim, A., Maier, D. M., Scott, K., Galanko, J. A., & Ringel, Y. (2015) · American Journal of Gastroenterology · doi:10.1038/ajg.2015.220 · Cited by 141
Self-citationNew treatments and therapeutic targets for IBS and other functional bowel disorders
Simrén, M., & Tack, J. F. (2018) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-018-0034-5 · Cited by 161
Fecal Microbiota Alterations Associated With Diarrhea-Predominant Irritable Bowel Syndrome
Zhuang, X., Tian, Z., Li, L., Zeng, Z., Chen, M., & Xiong, L. (2018) · Frontiers in Microbiology · doi:10.3389/fmicb.2018.01600 · Cited by 150
“Two randomized double-blind placebo controlled phase 3 trials (TARGET 1 and TARGET 2) had shown the efficacy of a 2 week course of rifaximin for global IBS symptoms and bloating in IBS-D patients (Pimentel et al., 2011).”
BackgroundThe Role of Antibiotics in Gut Microbiota Modulation: The Eubiotic Effects of Rifaximin
Ponziani, F. R., Scaldaferri, F., Petito, V., Sterbini, F. P., Pecere, S., Lopetuso, L. R., Palladini, A., Gerardi, V., Masucci, L., Pompili, M., et al. (2016) · Digestive Diseases · doi:10.1159/000443361 · Cited by 148
Mearin, F., Ciriza, C., Mínguez, M., Rey, E., Mascort, J. J., Peña, E., Cañones, P., & Júdez, J. (2016) · Revista Española de Enfermedades Digestivas · doi:10.17235/reed.2016.4389/2016 · Cited by 139
Ghoshal, U., Shukla, R., Srivastava, D., & Ghoshal, U. C. (2016) · Gut and Liver · doi:10.5009/gnl15588 · Cited by 136
“Therapeutic manipulation of gut flora using antibiotic or probiotic is known to improve IBS symptoms.(5,6) Role of gut microbiota and its alterations is being explored in the pathogenesis of this enigmatic disorder.”
BackgroundIrritable bowel syndrome diagnosis and management: A simplified algorithm for clinical practice
Moayyedi, P., Mearin, F., Azpiroz, F., Andresen, V., Barbara, G., Corsetti, M., Emmanuel, A., Hungin, A. P. S., Layer, P., Stanghellini, V., et al. (2017) · United European Gastroenterology Journal · doi:10.1177/2050640617731968 · Cited by 135
“In randomised controlled trials in patients with non-constipated IBS, two weeks of rifaximin treatment provided adequate relief of global IBS symptoms and individual symptoms of loose stools, abdominal pain, and bloating.(52) However, this effect gradually disappears and re-treatment is necessary in a large proportion…”
BackgroundChang, L., Lembo, A. J., & Sultan, S. (2014) · Gastroenterology · doi:10.1053/j.gastro.2014.09.002 · Cited by 142
Self-citationRifamycins, Alone and in Combination
Rothstein, D. M. (2016) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a027011 · Cited by 145
“In fact, a retrospective study of patients who had received multiple treatments suggested that retreatment with rifaximin provided comparable benefit to some subjects (Pimentel et al. 2011b).”
BackgroundManagement Options for Irritable Bowel Syndrome
Camilleri, M. (2018) · Mayo Clinic Proceedings · doi:10.1016/j.mayocp.2018.04.032 · Cited by 109
“Effectiveness according to IBS subtype has been studied in only 2 RCTs.84,85 Three trials of antidepressants in IBS have found no correlation between improvement in IBS symptoms and depression scores,86-88 and a fourth trial of a TCA revealed greater benefit in nondepressed individuals.89 Three open-label trials have…”
InfluentialFukui, H., Xu, X., & Miwa, H. (2018) · Journal of Neurogastroenterology and Motility · doi:10.5056/jnm18071 · Cited by 128
Efficacy of Probiotics in Irritable Bowel Syndrome: Systematic Review and Meta-analysis
Goodoory, V. C., Khasawneh, M., Black, C. J., Quigley, E. M. M., Moayyedi, P., & Ford, A. C. (2023) · Gastroenterology · doi:10.1053/j.gastro.2023.07.018 · Cited by 128
Increased Risk for Irritable Bowel Syndrome After Acute Diverticulitis
Cohen, E. R., Fuller, G., Bolus, R. R., Modi, R., Vu, M., Shahedi, K., Shah, R., Atia, M. A., Kurzbard, N., Sheen, V., et al. (2013) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2013.03.007 · Cited by 133
Diagnosis and Management of Small Intestinal Bacterial Overgrowth
Bohm, M., Siwiec, R. M., & Wo, J. M. (2013) · Nutrition in Clinical Practice · doi:10.1177/0884533613485882 · Cited by 127
Intestinal Microbiota and its Role in Irritable Bowel Syndrome (IBS)
Öhman, L., & Simrén, M. (2013) · Current Gastroenterology Reports · doi:10.1007/s11894-013-0323-7 · Cited by 138
Zhu, Y., Zheng, X., Cong, Y., Chu, H., Fried, M., Dai, N., & Fox, M. (2013) · American Journal of Gastroenterology · doi:10.1038/ajg.2013.198 · Cited by 122
Mencarelli, A., Renga, B., Palladino, G., D’Amore, C., Ricci, P., Distrutti, E., Barbanti, M., Baldelli, F., & Fiorucci, S. (2011) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2011.06.058 · Cited by 131
Modulation of microbiota as treatment for intestinal inflammatory disorders: An uptodate
Gallo, A., Passaro, G., Gasbarrini, A., Landolfi, R., & Montalto, M. (2016) · World Journal of Gastroenterology · doi:10.3748/wjg.v22.i32.7186 · Cited by 119
Management of Chronic Abdominal Distension and Bloating
Lacy, B. E., Cangemi, D. J., & Vázquez‐Roque, M. I. (2020) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2020.03.056 · Cited by 142
Irritable bowel syndrome: treatment based on pathophysiology and biomarkers
Camilleri, M., & Boeckxstaens, G. E. (2022) · Gut · doi:10.1136/gutjnl-2022-328515 · Cited by 153
Oral Iron Supplementation—Gastrointestinal Side Effects and the Impact on the Gut Microbiota
Bloor, S. R., Schutte, R., & Hobson, A. R. (2021) · Microbiology Research · doi:10.3390/microbiolres12020033 · Cited by 117
Irritable bowel syndrome and gut microbiota
Canakis, A., Haroon, M., & Weber, H. C. (2019) · Current Opinion in Endocrinology Diabetes and Obesity · doi:10.1097/med.0000000000000523 · Cited by 149
“Rifaximin’s utility in treating diarrheapredominant IBS was demonstrated in three largescale double blind placebo controlled clinical trials known as the TARGET 1, 2 and 3, or the Targeted, nonsystemic Antibiotic Rifaximin Gut-selective Evaluation of Treatment for IBS [81,82].”
BackgroundWei, L., Singh, R., Ro, S., & Ghoshal, U. C. (2021) · JGH Open · doi:10.1002/jgh3.12528 · Cited by 146
Intestinal microbiota and immune function in the pathogenesis of irritable bowel syndrome
Ringel, Y., & Maharshak, N. (2013) · American Journal of Physiology-Gastrointestinal and Liver Physiology · doi:10.1152/ajpgi.00207.2012 · Cited by 115
Self-citationConsensus report: faecal microbiota transfer – clinical applications and procedures
König, J., Siebenhaar, A., Högenauer, C., Arkkila, P., Nieuwdorp, M., Norén, T., Ponsioen, C. Y., Rosien, U., Rossen, N. G., Satokari, R., et al. (2017) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.13868 · Cited by 114
Cremon, C., Guglielmetti, S., Gargari, G., Taverniti, V., Castellazzi, A. M., Valsecchi, C., Tagliacarne, C., Fiore, W., Bellini, M., Bertani, L., et al. (2018) · United European Gastroenterology Journal · doi:10.1177/2050640617736478 · Cited by 112
Shah, A., Morrison, M., Burger, D. C., Martin, N., Rich, J., Jones, M., Koloski, N. A., Walker, M. M., Talley, N. J., & Holtmann, G. (2019) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.15133 · Cited by 122
Second Asian Consensus on Irritable Bowel Syndrome
Gwee, K. A., Gonlachanvit, S., Ghoshal, U. C., Chua, A. S. B., Miwa, H., Wu, J., Bak, Y.-T., Lee, O. Y., Lu, C.-L., Park, H., et al. (2019) · Journal of Neurogastroenterology and Motility · doi:10.5056/jnm19041 · Cited by 112
“3 July, 2019 (343-362) intestinal bacterial overgrowth (SIBO) more often among patients with IBS than healthy subjects.(65) Moreover, multiple studies documenting improvement in IBS symptoms following treatment with”
BackgroundInternational consensus statement on microbiome testing in clinical practice
Porcari, S., Mullish, B. H., Asnicar, F., Ng, S. C., Zhao, L., Hansen, R., O’Toole, P. W., Raes, J., Hold, G. L., Putignani, L., et al. (2024) · The Lancet. Gastroenterology & hepatology · doi:10.1016/s2468-1253(24)00311-x · Cited by 146
The microbiota link to irritable bowel syndrome: An emerging story
Jeffery, I. B., Quigley, E. M. M., Öhman, L., Simrén, M., & O'Toole, P. W. (2012) · Gut Microbes · doi:10.4161/gmic.21772 · Cited by 110
“While a convincing history of the onset of IBS in relation to gastroenteritis is present in only a minority of IBS subjects,(3) a role for the microbiota in the majority can be imputed from some, albeit circumstantial, pieces of evidence which include upregulation of Toll-like receptor(4) increased levels of defensins…”
BackgroundPortincasa, P., Bonfrate, L., Scribano, M., Kohn, A., Caporaso, N., Festi, D., Campanale, M. C., Di Rienzo, T., Guarino, M., Taddia, M., et al. (2016) · Journal of Gastrointestinal and Liver Diseases · doi:10.15403/jgld.2014.1121.252.ccm · Cited by 109
“Definitive treatment options are still missing in IBS patients with either diarrhea or constipation and might include from time to time dietary modification, laxatives, lubiproston, linaclotide, antidiarrhoeals, alosetron, rifaximin, eluxadoline [2-5].”
BackgroundIrritable Bowel Syndrome: A Review and Update
Occhipinti, K., & Smith, J. (2012) · Clinics in Colon and Rectal Surgery · doi:10.1055/s-0032-1301759 · Cited by 105
Intestinal microbiota in pathophysiology and management of irritable bowel syndrome.
(2014) · PubMed Central · doi:10.3748/wjg.v20.i27.8886 · Cited by 106
Microflora Modulation of Motility
Quigley, E. M. M. (2011) · Journal of Neurogastroenterology and Motility · doi:10.5056/jnm.2011.17.2.140 · Cited by 106
Irritable bowel syndrome in children: Current knowledge, challenges and opportunities
Devanarayana, N. M., & Rajindrajith, S. (2018) · World Journal of Gastroenterology · doi:10.3748/wjg.v24.i21.2211 · Cited by 106
Schoenfeld, P., Pimentel, M., Chang, L., Lembo, A., Chey, W. D., Yu, J., Paterson, C., Bortey, E., & Forbes, W. P. (2014) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.12735 · Cited by 106
“Furthermore, a significantly greater percentage of patients treated with rifaximin experienced adequate relief of global symptoms of IBS throughout the 12-week studies (2 weeks of treatment and 10 weeks of follow-up).(9) A phase 2b dose-ranging study also demonstrated efficacy of rifaximin vs.”
BackgroundResultSelf-citationGiamarellos-Bourboulis, E., Tang, J., Pyleris, E., Pistiki, A., Barbatzas, C., Brown, J., Lee, C. C., Harkins, T. T., Kim, G., Weitsman, S., et al. (2015) · Scandinavian Journal of Gastroenterology · doi:10.3109/00365521.2015.1027261 · Cited by 106
“The support for this concept has been based on breath test studies [6,7,25–28], small bowel culture studies [8,9], and the success of antibiotic treatments in improving IBS symptoms [6,29,30].”
BackgroundSelf-citationImmune activation in irritable bowel syndrome: what is the evidence?
Aguilera‐Lizarraga, J., Hussein, H., & Boeckxstaens, G. E. (2022) · Nature reviews. Immunology · doi:10.1038/s41577-022-00700-9 · Cited by 135
New insights into the pathogenesis and treatment of irritable bowel syndrome
Oświęcimska, J. M., Szymlak, A., Roczniak, W., Girczys-Połedniok, K., & Kwiecień, J. (2017) · Advances in Medical Sciences · doi:10.1016/j.advms.2016.11.001 · Cited by 133
Functional Dyspepsia: Diagnostic and Therapeutic Approaches
Sayuk, G. S., & Gyawali, C. P. (2020) · Drugs · doi:10.1007/s40265-020-01362-4 · Cited by 122
Singh, R., Zogg, H., Ghoshal, U. C., & Ro, S. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.808195 · Cited by 123
Ghoshal, U. C. (2014) · World Journal of Gastroenterology · doi:10.3748/wjg.v20.i10.2482 · Cited by 103
No distinct microbiome signature of irritable bowel syndrome found in a Swedish random population
Hugerth, L. W., Andreasson, A., Talley, N. J., Forsberg, A. M., Kjellström, L., Schmidt, P. T., Agreus, L., & Engstrand, L. (2020) · Gut · doi:10.1136/gutjnl-2019-318717 · Cited by 102
Binda, G. A., Cuomo, R., Laghi, A., Nascimbeni, R., Serventi, A., Bellini, D., Gervaz, P., & Annibale, B. (2015) · Techniques in Coloproctology · doi:10.1007/s10151-015-1370-x · Cited by 105
Small Intestinal Bacterial Overgrowth and Other Intestinal Disorders
Ghoshal, U. C., & Ghoshal, U. (2017) · Gastroenterology Clinics of North America · doi:10.1016/j.gtc.2016.09.008 · Cited by 139
Chung, C.-S., Chang, P.-F., Liao, C.-H., Lee, T.-H., Chen, Y., Lee, Y.-C., Wu, M.-S., Wang, H.-P., & Ni, Y.-H. (2016) · Scandinavian Journal of Gastroenterology · doi:10.3109/00365521.2015.1116107 · Cited by 101
The gut microbiota as a key regulator of visceral pain
O’Mahony, S. M., Dinan, T. G., & Cryan, J. F. (2016) · Pain · doi:10.1097/j.pain.0000000000000779 · Cited by 108
Andrews, C. N., Griffiths, T. A., Kaufman, J., Vergnolle, N., Surette, M. G., & Rioux, K. P. (2011) · Alimentary Pharmacology & Therapeutics · doi:10.1111/j.1365-2036.2011.04732.x · Cited by 97
“Furthermore, treatment with the non-absorbable antibiotic rifaximin has been recently shown to improve symptoms in nonconstipation IBS in randomised studies.(11) A number of immunological abnormalities of uncertain significance have been described in populations with IBS, among them elevated numbers of colonic mucosal…”
BackgroundSoldi, S., Vasileiadis, S., Uggeri, F., Campanale, M. C., Morelli, L., Calanni, F., Grimaldi, M., Gasbarrini, A., & Fogli, M. V. (2015) · Clinical and Experimental Gastroenterology · doi:10.2147/ceg.s89999 · Cited by 96
Black, C. J., Yiannakou, Y., Guthrie, E. A., West, R., Houghton, L. A., & Ford, A. C. (2021) · American Journal of Gastroenterology · doi:10.14309/ajg.0000000000000975 · Cited by 94
Rifaximin Exerts Beneficial Effects Independent of its Ability to Alter Microbiota Composition
Kang, D. J., Kakiyama, G., Betrapally, N. S., Herzog, J., Nittono, H., Hylemon, P. B., Zhou, H., Carroll, I. M., Yang, J., Gillevet, P. M., et al. (2016) · Clinical and Translational Gastroenterology · doi:10.1038/ctg.2016.44 · Cited by 106
“Modulating the gut milieu is a target for treatments that ameliorate the systemic pro-inflammatory milieu in several relevant human diseases such as hepatic encephalopathy (HE), irritable bowel syndrome, and inflammatory bowel diseases.(1,2) Rifaximin, which is widely viewed as a nonabsorbable antibiotic, has clinical…”
BackgroundStress-Related Alterations of Visceral Sensation: Animal Models for Irritable Bowel Syndrome Study
Larauche, M., Mulak, A., & Taché, Y. (2011) · Journal of Neurogastroenterology and Motility · doi:10.5056/jnm.2011.17.3.213 · Cited by 93
Microbiota intestinal en la salud y la enfermedad
Icaza-Chávez, M. E. (2013) · Revista de Gastroenterología de México · doi:10.1016/j.rgmx.2013.04.004 · Cited by 91
Pinn, D. M., Aroniadis, O. C., & Brandt, L. J. (2015) · Neurogastroenterology & Motility · doi:10.1111/nmo.12479 · Cited by 91
Ghoshal, U. C., Sachdeva, S., Ghoshal, U., Misra, A., Puri, A. S., Pratap, N., Shah, A., Rahman, M. M., Gwee, K. A., Tan, V. P. Y., et al. (2022) · Indian Journal of Gastroenterology · doi:10.1007/s12664-022-01292-x · Cited by 109
Pimentel, M., Morales, W., Pokkunuri, V. B., Brikos, C., Kim, S. M., Kim, S., Τriantafyllou, Κ., Weitsman, S. R., Marsh, Z. A., Marsh, E., et al. (2014) · Digestive Diseases and Sciences · doi:10.1007/s10620-014-3435-5 · Cited by 88
“The level of SIBO in turn appears to correlate with the level of altered bowel function, both in this rat model [31] and in human subjects [23].”
BackgroundSelf-citationHuang, H. L., Chen, H. T., Luo, Q. L., Xu, H. M., He, J., Li, Y. Q., Zhou, Y. L., Yao, F., Nie, Y. Q., & Zhou, Y. J. (2019) · Journal of Digestive Diseases · doi:10.1111/1751-2980.12756 · Cited by 89
“Imbalances in gut microbiota may negatively influence intestinal secretion and motility, even causing IBS.”
BackgroundMethodInfluentialPharmacologic and Complementary and Alternative Medicine Therapies for Irritable Bowel Syndrome
Chey, W. D., Maneerattaporn, M., & Saad, R. (2011) · Gut and Liver · doi:10.5009/gnl.2011.5.3.253 · Cited by 89
“difficile associated diarrhea or ischemic colitis reported in the phase 3 trials.(91) Despite these very encouraging results, a number of important questions remain regarding the role of antibiotic therapy in IBS patients.”
BackgroundSelf-citationAcosta, A., Camilleri, M., Shin, A., Nord, S. L., O'Neill, J., Gray, A. V., Lueke, A. J., Donato, L. J., Burton, D. D., Szarka, L. A., et al. (2016) · Clinical and Translational Gastroenterology · doi:10.1038/ctg.2016.32 · Cited by 88
Effect of rifaximin on gut microbiota composition in advanced liver disease and its complications
Ponziani, F. R., Gerardi, V., Pecere, S., D'Aversa, F., Lopetuso, L., Zocco, M. A., Pompili, M., & Gasbarrini, A. (2015) · World Journal of Gastroenterology · doi:10.3748/wjg.v21.i43.12322 · Cited by 95
Low-level inflammation, immunity, and brain-gut axis in IBS: unraveling the complex relationships
Yuan, Y., Wang, X., Huang, S., Wang, H., & Shen, G.-M. (2023) · Gut Microbes · doi:10.1080/19490976.2023.2263209 · Cited by 114
Upper gastrointestinal microbiota and digestive diseases
Wang, Z.-K. (2013) · World Journal of Gastroenterology · doi:10.3748/wjg.v19.i10.1541 · Cited by 88
Spiller, R., Pélerin, F., Cayzeele Decherf, A., Maudet, C., Housez, B., Cazaubiel, M., & Jüsten, P. (2016) · United European Gastroenterology Journal · doi:10.1177/2050640615602571 · Cited by 87
“Its role in causing IBS symptoms is contentious but some studies suggest a modest benefit from antibiotic use.(28) At present it is not usually used in screening patients subjected to clinical trials but if a more reliable method of testing was available this might be reconsidered in the future, especially when testin…”
BackgroundSafety of Eluxadoline in Patients with Irritable Bowel Syndrome with Diarrhea
Cash, B. D., Lacy, B. E., Schoenfeld, P. S., Dove, L. S., & Covington, P. S. (2017) · American Journal of Gastroenterology · doi:10.1038/ajg.2016.542 · Cited by 88
Bloating and Abdominal Distension: Old Misconceptions and Current Knowledge
Malagelada, J. R., Accarino, A. M., & Azpiroz, F. (2017) · The American Journal of Gastroenterology · doi:10.1038/ajg.2017.129 · Cited by 93
Abdominal Bloating: Pathophysiology and Treatment
Seo, A. Y., Kim, N., & Oh, D. H. (2013) · Journal of Neurogastroenterology and Motility · doi:10.5056/jnm.2013.19.4.433 · Cited by 98
“4 October, 2013 (433-453) center trial proved that rifaximin provided significant improvement of IBS symptoms including abdominal pain and bloating in non-constipated IBS patients.(109) Pimentel et al(110) also suggested that neomycin normalized lactulose breath test and it contributed to the reduction of bloating in…”
BackgroundEffects of Rifaximin Treatment and Retreatment in Nonconstipated IBS Subjects
Pimentel, M., Morales, W., Chua, K., Barlow, G., Weitsman, S., Kim, G., Amichai, M. M., Pokkunuri, V., Rook, E., Mathur, R., et al. (2011) · Digestive Diseases and Sciences · doi:10.1007/s10620-011-1728-5 · Cited by 86
“Based on the principle that a significant number of IBS patients may have gut flora alteration, a number of randomized controlled trials have been conducted examining the effect of antibiotics in IBS [5–8].”
BackgroundResultInfluentialSelf-citationYuan, F., Ni, H., Asche, C. V., Kim, M., Walayat, S., & Ren, J. (2017) · Current Medical Research and Opinion · doi:10.1080/03007995.2017.1292230 · Cited by 86
Napolitano, M., Fasulo, E., Ungaro, F., Massimino, L., Sinagra, E., Danese, S., & Mandarino, F. V. (2023) · Microorganisms · doi:10.3390/microorganisms11102369 · Cited by 107
“In addition, the efficacy of rifaximin on clinical manifestation ( p 0.05) was confirmed in patients with IBS-D, independently from the presence of concomitant SIBO [122].”
BackgroundInfluentialFord, A. C., & Talley, N. J. (2012) · BMJ · doi:10.1136/bmj.e5836 · Cited by 84
Fodor, A. A., Pimentel, M., Chey, W. D., Lembo, A., Golden, P. L., Israel, R. J., & Carroll, I. M. (2019) · Gut Microbes · doi:10.1080/19490976.2018.1460013 · Cited by 84
“The efficacy and safety of rifaximin, approved for the treatment of adults with diarrhoea-predominant IBS (IBS-D), have been demonstrated in various clinical studies.(27-32) In 2 identically designed, double-blind, phase 3 studies (Targeted, non-systemic Antibiotic Rifaximin Gutselective Evaluation of Treatment for IB…”
BackgroundSelf-citationRezaie, A., Heimanson, Z., McCallum, R., & Pimentel, M. (2019) · American Journal of Gastroenterology · doi:10.14309/ajg.0000000000000444 · Cited by 84
Self-citationEffect of commensals and probiotics on visceral sensitivity and pain in irritable bowel syndrome
Theodorou, V., Ait-Belgnaoui, A., Agostini, S., & Eutamene, H. (2014) · Gut Microbes · doi:10.4161/gmic.29796 · Cited by 83
Modulation of the gut microbiota: a focus on treatments for irritable bowel syndrome
Harris, L. A., & Baffy, N. (2017) · Postgraduate Medicine · doi:10.1080/00325481.2017.1383819 · Cited by 83
“Rifaximin 550 mg three times daily for 2 weeks has been evaluated in two phase III, identically designed, randomized, placebo-controlled IBS-D trials [109].”
BackgroundMethodPost-infectious IBS, tropical sprue and small intestinal bacterial overgrowth: the missing link
Ghoshal, U. C., & Gwee, K. (2017) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/nrgastro.2017.37 · Cited by 86
Maconi, G., Barbara, G., Bosetti, C., Cuomo, R., & Annibale, B. (2011) · Diseases of the Colon & Rectum · doi:10.1097/dcr.0b013e318223cb2b · Cited by 88
Management of the multiple symptoms of irritable bowel syndrome
Simrén, M., Törnblom, H., Palsson, O. S., & Whitehead, W. E. (2017) · The Lancet. Gastroenterology & hepatology · doi:10.1016/s2468-1253(16)30116-9 · Cited by 97
How to calculate sample size in animal and human studies
Zhang, X., & Hartmann, P. (2023) · Frontiers in Medicine · doi:10.3389/fmed.2023.1215927 · Cited by 96
Enteric bacterial proteases in inflammatory bowel disease- pathophysiology and clinical implications
Carroll, I. M. (2013) · World Journal of Gastroenterology · doi:10.3748/wjg.v19.i43.7531 · Cited by 80
Evaluation of Harm in the Pharmacotherapy of Irritable Bowel Syndrome
Shah, E. D., Kim, S., Chong, K., Lembo, A. J., & Pimentel, M. (2012) · The American Journal of Medicine · doi:10.1016/j.amjmed.2011.08.026 · Cited by 81
Self-citationGhoshal, U. C., Srivastava, D., Misra, A., & Ghoshal, U. (2016) · European Journal of Gastroenterology & Hepatology · doi:10.1097/meg.0000000000000557 · Cited by 81
Methanogens in Human Health and Disease
Pimentel, M., Gunsalus, R. P., Rao, S. S., & Zhang, H. (2012) · The American Journal of Gastroenterology Supplements · doi:10.1038/ajgsup.2012.6 · Cited by 78
Self-citationBarbara, G., Zecchi, L., Barbaro, R., Cremon, C., Bellacosa, L., Marcellini, M., De Giorgio, R., Corinaldesi, R., & Stanghellini, V. (2012) · Journal of Clinical Gastroenterology · doi:10.1097/mcg.0b013e318264e918 · Cited by 79
Eskesen, D., Jespersen, L., Michelsen, B., Whorwell, P. J., Müller-Lissner, S., & Morberg, C. M. (2015) · British Journal of Nutrition · doi:10.1017/s0007114515003347 · Cited by 78
“The sample size calculation was based on a onesided α level of 0·0125 to account for two primary end points, an assumed placebo response rate of 40 % and a treatment difference of 10 % in responder rates based on previously published studies((23,28)).”
MethodRole of the Duodenum in the Pathogenesis of Functional Dyspepsia: A Paradigm Shift
Jung, H., & Talley, N. J. (2018) · Journal of Neurogastroenterology and Motility · doi:10.5056/jnm18060 · Cited by 80
“the intestinal gut microbiota, which has been demonstrated in IBS studies.(96) Dietary factors are known to precipitate or exacerbate FD symptoms.”
BackgroundBarboza, J. L., Okun, M. S., & Moshiree, B. (2015) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2015.1086747 · Cited by 77
“The Phase III, placebo-controlled RCTs, TARGET 1 and 2 trials, showed that a 2-week treatment of rifaximin has shown relief of IBS symptoms, bloating, abdominal pain and loose/watery stools in patients with IBS without constipation [86].”
BackgroundMethodPimentel, M. (2016) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.13437 · Cited by 75
“001), and both of these improvements were maintained for at least 12 weeks post-treatment.(13)A third randomised,”
BackgroundMethodInfluentialSelf-citationTait, C., & Sayuk, G. S. (2021) · European Journal of Internal Medicine · doi:10.1016/j.ejim.2020.12.023 · Cited by 84
Metadata
- Authors
- Pimentel, M., Lembo, A., Chey, W. D., Zakko, S., Ringel, Y., Yu, J., Mareya, S. M., Shaw, A. L., Bortey, E., & Forbes, W. P.
- Affiliations
- Cedars-Sinai Medical Center (US)
- Beth Israel Deaconess Medical Center (US)
- Michigan Medicine (US)
- Bristol Hospital (US)
- University of North Carolina at Chapel Hill (US)
- Salix Pharmaceuticals (United States) (US)
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2011-01-06
- Volume
- 364
- Issue
- 1
- Pages
- 22-32
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2149216059
- Cited by
- 1,036
- References
- 21
- Citations by year
- 2026: 51 · 2025: 46 · 2024: 36 · 2023: 56 · 2022: 51 · 2021: 65 · 2020: 56 · 2019: 51 · 2018: 65 · 2017: 74 · 2016: 87 · 2015: 70 · 2014: 95 · 2013: 73 · 2012: 87
- FWCI
- 106.03
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Carolina Digital Repository (University of North Carolina at Chapel Hill) (submittedVersion)
- UNC Libraries
- Topics
- Health Sciences › Medicine › Gastroenterology › Gastrointestinal motility and disorders
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Gut microbiota and health
- Health Sciences › Medicine › Pediatrics, Perinatology and Child Health › Infant Health and Development
- Keywords
- rifaximin, gut microbiota, bloating, abdominal pain, stool consistency, symptom relief, antibiotic therapy, IBS pathophysiology, TARGET trial, adverse events
- MeSH terms
- Rifaximin, Aged, Anti-Bacterial Agents, Diarrhea, Double-Blind Method, Female, Humans, Male, Middle Aged, Rifamycins, Abdominal Pain, Irritable Bowel Syndrome
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.